Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -48.34% is 99% above its 4-year average of -3907.18%, near the high end of its 4-year range (-19435.32%–-2.43%).
41.97% below its 12-month average of -34.05%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.99%.
RETURN ON ASSETS (ROA)
-48.34%
RETURN ON ASSETS (ROA) AVG TTM
-34.05%
RETURN ON ASSETS (ROA) AVG 3Y
-4876.46%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-41.97%
CURRENT VS 3Y AVG
+99.01%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 782 covered companies
CURRENT VS SECTOR MEDIAN
-53.58%
vs the sector median at left
BridgeBio Oncology Therapeutics Inc.
Market Cap
$285.98M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
N/A
Market Cap
$286.40M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$286.50M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
Market Cap
$287.37M
Return on Assets (ROA)
-17.87%
TTM Avg
-36.13%
3Y Avg
-48.35%
5Y Avg
-41.88%
Market Cap
$288.39M
Return on Assets (ROA)
-13.93%
TTM Avg
-17.93%
3Y Avg
-26.92%
5Y Avg
-24.25%
Market Cap
$282.30M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$279.98M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
Market Cap
$294.51M
Return on Assets (ROA)
-104.42%
TTM Avg
-76.93%
3Y Avg
-55.08%
5Y Avg
-54.19%
Market Cap
$277.05M
Return on Assets (ROA)
-5.36%
TTM Avg
-34.75%
3Y Avg
-39.14%
5Y Avg
-23.69%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $285.98M | -48.34% | -34.05% | -4876.46% | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.40M | -35.03% | -13.04% | -43.14% | -55.84% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $286.50M | -128.66% | -214.31% | -145.75% | -133.94% |
| Sagimet Biosciences Inc. (SGMT)vs › | $287.37M | -17.87% | -36.13% | -48.35% | -41.88% |
| Standard BioTools Inc. (LAB)vs › | $288.39M | -13.93% | -17.93% | -26.92% | -24.25% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $282.30M | -26.24% | -12.09% | -27.60% | -33.24% |
| Aurora Cannabis Inc. (ACB)vs › | $279.98M | -18.18% | -10.00% | -29.10% | -54.94% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $294.51M | -104.42% | -76.93% | -55.08% | -54.19% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | -5.36% | -34.75% | -39.14% | -23.69% |
| Fate Therapeutics, Inc. (FATE)vs › | $273.91M | -48.44% | -42.51% | -39.18% | -34.60% |
ROA
-48.3%
ROE
-56.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -29.90% |
| 2024-12-31 | -38.20% |
| 2023-12-31 | -19435.32% |
| 2022-12-31 | -2.43% |
| 2021-12-31 | -30.05% |
